CA2361919A1 - Inhibiteurs lactame du facteur xa et methode associee - Google Patents

Inhibiteurs lactame du facteur xa et methode associee Download PDF

Info

Publication number
CA2361919A1
CA2361919A1 CA002361919A CA2361919A CA2361919A1 CA 2361919 A1 CA2361919 A1 CA 2361919A1 CA 002361919 A CA002361919 A CA 002361919A CA 2361919 A CA2361919 A CA 2361919A CA 2361919 A1 CA2361919 A1 CA 2361919A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
cycloheteroalkyl
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002361919A
Other languages
English (en)
Inventor
Gregory S. Bisacchi
Steven M. Seiler
R. Michael Lawrence
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2361919A1 publication Critical patent/CA2361919A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des inhibiteurs lactame représentés par la formule (I) dans laquelle X représente (2) ou (3), Y représente O ou S et R?4¿ représente (4), R?7¿O- ou R?8¿, et R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, R?6¿, R?7¿ et R?8¿ sont tels que définis dans cette invention. Ces composés sont des inhibiteurs du facteur Xa et sont ainsi d'utiles anticoagulants. L'invention concerne également une méthode de traitement des maladies cardio-vasculaires associées aux thromboses.
CA002361919A 1999-02-09 2000-01-27 Inhibiteurs lactame du facteur xa et methode associee Abandoned CA2361919A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11937499P 1999-02-09 1999-02-09
US60/119,374 1999-02-09
PCT/US2000/001859 WO2000047563A1 (fr) 1999-02-09 2000-01-27 INHIBITEURS LACTAME DU FACTEUR Xa ET METHODE ASSOCIEE

Publications (1)

Publication Number Publication Date
CA2361919A1 true CA2361919A1 (fr) 2000-08-17

Family

ID=22384077

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002361919A Abandoned CA2361919A1 (fr) 1999-02-09 2000-01-27 Inhibiteurs lactame du facteur xa et methode associee

Country Status (5)

Country Link
EP (1) EP1175405A4 (fr)
JP (1) JP2002536437A (fr)
AU (1) AU756174B2 (fr)
CA (1) CA2361919A1 (fr)
WO (1) WO2000047563A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344450B1 (en) * 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
AU2001243441B2 (en) * 2000-03-21 2004-11-25 Smithkline Beecham Corporation Protease inhibitors
WO2001079261A1 (fr) * 2000-04-14 2001-10-25 Corvas International, Inc. Derives de tetrahydro-azepinone servant d'inhibiteurs de la thrombine
US6544981B2 (en) 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
WO2002080853A2 (fr) 2001-04-09 2002-10-17 Bristol-Myers Squibb Company Inhibiteurs heterocycliques fusionnes du facteur xa
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0127568D0 (en) * 2001-11-16 2002-01-09 Glaxo Group Ltd Chemical compounds
AU2003302238A1 (en) 2002-12-03 2004-06-23 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
US7199149B2 (en) * 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1247698B (it) * 1990-06-21 1994-12-30 Sigma Tau Ind Farmaceuti 1-alchil-3-(acilammino)-e-caprolattami quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
JPH10503176A (ja) * 1994-06-17 1998-03-24 コーバス インターナショナル， インコーポレイテッド 酵素インヒビターとしての３−アミノ−２−オキソ−１−ピペリジン酢酸誘導体
GB9420763D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
EP0937073A2 (fr) * 1996-10-11 1999-08-25 Cor Therapeutics, Inc. Inhibiteurs competitifs du facteur xa
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase

Also Published As

Publication number Publication date
JP2002536437A (ja) 2002-10-29
EP1175405A4 (fr) 2002-05-15
WO2000047563A1 (fr) 2000-08-17
AU2630000A (en) 2000-08-29
EP1175405A1 (fr) 2002-01-30
AU756174B2 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
US6511977B1 (en) Potassium channel inhibitors and method
US6642252B2 (en) Acid derivatives useful as serine protease inhibitors
AU2007212236B2 (en) Piperidinyl derivatives as modulators of chemokine receptor activity
US5965562A (en) Aroyl-piperidine derivatives
CA2176037C (fr) Derives antithrombotiques d'amidinophenylalanine et d'amidinopyridylalanine
JP2002536411A (ja) Ｘａ因子のラクタム系阻害剤および方法
US6344450B1 (en) Lactam compounds and their use as inhibitors of serine proteases and method
AU4797000A (en) Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6713467B2 (en) Acid derivatives useful as serine protease inhibitors
AU756174B2 (en) Lactam inhibitors of FXa and method
US6544981B2 (en) Lactam inhibitors of factor Xa and method
WO2013182638A1 (fr) 2-aminothiazinylhétéroaryles en tant qu'inhibiteurs de bace1 pour le traitement de la maladie d'alzheimer
WO2007008142A1 (fr) Dérivés de sulfonamides hétérocycliques en tant qu'inhibiteurs du facteur xa
AU2019242518A1 (en) Compound with anticancer activity
CA2370607A1 (fr) Inhibiteurs d'echange sodium-protons a base de guandines d'acyle bicyclique et procede correspondant
WO2004000788A1 (fr) Composes aniline a substitution ureido utiles comme inhibiteurs de serines proteases
AU9376798A (en) Pyrazinone thrombin inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead